Superscript

Brain Repair Is Our Mission

Novel therapies for neuropathic pain and devastating disorders of the nervous system

ABout OUR MISSION

What we do make perfect  sense

130 million people suffer from neuropathic pain, epilepsy or neurodegenerative disorders, conditions that literally  rob people's lives.

Today's  treatments are either inadequate or non-existing and the extent of  human suffering cannot be described with words

new therapies are a must, and we are coMmitted to  make a change!   
ApproacH AND TECHNOLOGIES

Precision from patient to treatment

Millions of years of evolution can hardly be wrong. We develop precise biotherapeutics based on human proteins that through the evolution have been optimized for neuronal repair and function.

Our reparative biotherapeutics are tailored for disease subtypes diagnosed by biomarkers, pathology and genetics.

The biotherapeutics are delivered either by injection or locally by an implantable proprietary gene therapy device to facilitate the most efficient treatment of the disease.

ABout Us

Change through innovation

We are a clinical stage company motivated by the need to transform the treatments of patients suffering from pain and devastating neurological diseases. 

Building on an innovative tradition in science with deep roots in the Karolinska institute, we develop next generation biotherapeutics.

We have footprints in both Sweden and US to facilitate our global presence, research collaborations, and partnering to deliver value for patients and investors

Product Pipeline

New Generations Biotherapeutics

Our clinical candidate NeuRepair targets neuropathic pain with a novel mechanism and has demonstrated promising efficacy in patients suffering from painful lumbar radiculopathy, PLR (sciatica). 

NeuRepair is poised to become the first-in-class therapy for neuropathic pain affecting millions of patients.

Based on recombinant biologics and our proprietary gene therapy device platform, we have generated a pipeline of additional reparative products in preclinical development for multiple indications including Epilepsy and Parkinson's disease. 


Our Leadership Team


Lars Wahlberg, MD, PhD 

CEO/CMO

Neurosurgeon, translational scientist, and entrepreneur 

>20 years of biotechnology R&D experience in developing biologics-based therapies for neurological disorders 

Johan Lundkvist, As. Prof

COO/CSO

Neurobiologist and cellbiologist by training

Associate Professor at Karolinska Institute in 2005

>17 years industrial leadership  experience from small biotech start-ups  and large pharma within neurological disorders

An van Es-Johansson, MD 

 Head Clinical Development

Physician , entrepreneur with extensive Board experience

> 30 years international experience in big pharma and biotech companies with focus on Clinical Development, Regulatory and Pharmacovigilance

Bob Blomquist

Corporate Development 

Business leader with operational experience in Fortune 500 and new venture startups

>35 years of healthcare industry experience, including biopharmaceuticals, diagnostics and medical devices

Advisor to private equity and biopharma

Kristofer Svensson, B.Sc

CFO

B.Sc in Business Administration and Economics

 Held several executive finance positions in the medtech field Since 2017.

Thomas Pollare, MD, PhD 

Chairman<<

Experienced advisor and investor, including  partner and member of 3i Global Healthcare team

 > 25 years health care industry experience with several executive positions in major pharma companies and smaller biotechs

Experience from over 30 board positions 

NEWS


Oct 7th 2021 Lars Wahlberg, CEO,  presents at Vator Innovation Summit

Contact

Sinfonia Biotherapeutics AB


Hälsovägen 7, 14157 Huddinge, Sweden
 130 Franklin Street, STE2,Warren, RI, US
 

info@sinfoniabtx.com